J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 C l i n i c a l t r i a l s
2 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
L i r i l u m a b
4 l a n g u a g e s
● ا ل ع ر ب ي ة ● ف ا ر س ی ● I t a l i a n o ● 中 文
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Lirilumab (INN ) is a human monoclonal antibody designed for the treatment of cancer.[1] [2] KIR2DL1/2/3 .[3]
This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb .
Clinical trials
[ edit ]
A phase 2 clinical trial for acute myeloid leukemia (AML)[4] [5]
It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN),[6] [7]
As of November 2017[update] [8]
References
[ edit ]
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab , American Medical Association
^ Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N (September 2009). "Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells" . Blood . 114 (13 ): 2667–77. doi :10.1182/blood-2009-02-206532 . PMC 2756126 PMID 19553639 .
^ Clinical trial number NCT01687387 ClinicalTrials.gov
^ Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017
^ Clinical trial number NCT03341936 ClinicalTrials.gov
^ Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017
^ lirilumab trials
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Lirilumab&oldid=1228046651 " C a t e g o r i e s : ● D r u g s n o t a s s i g n e d a n A T C c o d e ● D r u g s d e v e l o p e d b y B r i s t o l M y e r s S q u i b b ● M o n o c l o n a l a n t i b o d i e s f o r t u m o r s ● M o n o c l o n a l a n t i b o d y s t u b s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n i s d i f f e r e n t f r o m W i k i d a t a ● C h e m i c a l s t h a t d o n o t h a v e a C h e m S p i d e r I D a s s i g n e d ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● D r u g s w i t h n o l e g a l s t a t u s ● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s ● D r u g s t h a t a r e a m o n o c l o n a l a n t i b o d y ● A r t i c l e s c o n t a i n i n g p o t e n t i a l l y d a t e d s t a t e m e n t s f r o m N o v e m b e r 2 0 1 7 ● A l l a r t i c l e s c o n t a i n i n g p o t e n t i a l l y d a t e d s t a t e m e n t s ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 9 J u n e 2 0 2 4 , a t 0 5 : 2 9 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
